Seedlings Life Science Ventures, LLC v. Pfizer Canada ULC, 2020 FC 505
Justice Grammond - 2020-04-09
Read full decision. Automatically generated summary:
The Defendant, Pfizer, was successful on all issues in an action for patent infringement brought by Seedlings. In this Court’s decision issued on January 2, 2020, the issue of costs was reserved: Seedlings Life Science Ventures, LLC v Pfizer Canada ULC, 2020 FC 1. Pfizer now seeks costs in a lump sum amount, over and above the tariff amount, based on 40% of its legal fees plus disbursements. For its part, Seedlings denies that costs on a lump sum basis are appropriate. It says that it should only be condemned to pay costs according to the Tariff set out in Schedule B to the Federal Courts Rules. Furthermore, Seedlings submits that Pfizer’s fees are unreasonable and that it has claimed disallowed or ineligible legal fees and disbursements. These are my reasons for awarding a lump sum of $2,629,062.00, inclusive of disbursements, on the basis of 25% of Pfizer’s reasonably incurred legal fees plus its reasonable disbursements.
Decision relates to:
- T-608-17 - SEEDLINGS LIFE SCIENCE VENTURES,LLC V. PFIZER CANADA INC.